mRNA Vaccines Were Just the Beginning — mRNA Therapeutics Will Replace Enzyme Replacement Therapy Entirely

COVID proved mRNA vaccines work. But vaccines are the least interesting application of mRNA technology.

Enzyme replacement therapies (ERTs) for rare genetic diseases cost $200K-$700K per year per patient and require IV infusion every 1-2 weeks for life. The enzymes are manufactured in CHO cells, purified extensively, and degraded rapidly in vivo. It's a terrible delivery mechanism kept alive because there was no alternative.

mRNA changes everything. Instead of injecting the protein, inject the instructions. LNP-encapsulated mRNA encoding the missing enzyme gets taken up by hepatocytes, which produce the enzyme endogenously. Duration: 1-2 weeks per dose. Manufacturing: scalable, synthetic. Cost: potentially 10-100x cheaper.

Moderna's mRNA-3927 for propionic acidemia and mRNA-3745 for glycogen storage disease are in clinical trials. Arcturus's ARCT-810 for ornithine transcarbamylase deficiency showed proof of concept.

Hypothesis: Within 10 years, mRNA therapeutics will replace >80% of current enzyme replacement therapies for rare diseases, reducing treatment costs by >90% while improving efficacy through continuous endogenous production.

Testable prediction: An mRNA therapeutic for a lysosomal storage disorder will demonstrate superior enzyme levels (>2x baseline) with monthly dosing vs. biweekly IV ERT, at <10% of the cost, in a Phase III trial by 2028.

BioDAOs should fund mRNA therapeutic development for ultra-rare diseases (<1000 patients) where pharma won't invest. The platform economics make small populations viable.